The historical rank and industry rank for Viyash Scientific's FCF Margin % or its related term are showing as below:
NSE:VIYASH'
s FCF Margin % Range Over the Past 10 Years
Min: -12.67 Med: 2.28 Max: 8.87
Current: 7.12
During the past 13 years, the highest FCF Margin % of Viyash Scientific was 8.87%. The lowest was -12.67%. And the median was 2.28%.
NSE:VIYASH's FCF Margin % is ranked better than 63.05% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs NSE:VIYASH: 7.12
Viyash Scientific FCF Margin % Related Terms
Viyash Scientific FCF Margin % Historical Data
* Premium members only.
The historical data trend for Viyash Scientific's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Viyash Scientific's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viyash Scientific FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viyash Scientific's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Viyash Scientific's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viyash Scientific (NSE:VIYASH) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Viyash Scientific and its competitors. According to the industry distribution chart, Viyash Scientific ranks #354 out of 958 companies in the Drug Manufacturers industry, placing it in the top 37%.
Is Viyash Scientific's FCF Margin % too high?
Viyash Scientific's current FCF Margin % is 0.00%. Based on the distribution chart, Viyash Scientific ranks #354 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Viyash Scientific has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viyash Scientific's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Viyash Scientific ranks #354 out of 958 companies for FCF Margin %. This puts Viyash Scientific in the upper half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Viyash Scientific and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viyash Scientific's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viyash Scientific stock overvalued right now?
Based on GuruFocus' analysis, Viyash Scientific (NSE:VIYASH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹171.37, compared to a current price of ₹269.30 — trading 57.1% above its estimated fair value. The current FCF Margin % is 0.00%. Viyash Scientific's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Viyash Scientific (NSE:VIYASH), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viyash Scientific (NSE:VIYASH) Overvalued in 2026?
Based on GuruFocus' analysis, Viyash Scientific stock appears to be overvalued.
The current stock price of ₹269.30 is trading 57.1% above its estimated GF Value™ of ₹171.37.
GuruFocus considers Viyash Scientific to be Significantly Overvalued.
Key valuation signals for NSE:VIYASH:
FCF Margin %: 0.00%
GF Value™: ₹171.37 vs. price of ₹269.30 (57.1% above fair value)
No single metric tells the full story. See the NSE:VIYASH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viyash Scientific Ltd is a pharmaceutical company with activities spanning formulations, active pharmaceutical ingredients (APIs), and intermediates. It is focused on research and development infrastructure for APIs and formulations. Its product portfolio spans several therapeutic areas, including ARV, cardiovascular, central nervous system, analgesics, antibiotics, antihistamines, diabetes, gastrointestinal, anticoagulants, and oncology.
72GF Score
Get the complete analysis for NSE:VIYASH
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VIYASH has been successfully added to your 
